Daily Schedule - Tuesday - September 23

Continental Breakfast
7:00 a.m.-8:00 a.m.
Plenary Session 5: Stem Cells
Session Chairperson: Emmanuelle Passegué, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, Calif.
8:00 a.m.-10:00 a.m.

Regulation of self-renewal in cancer stem cells
Pier Giuseppe Pelicci, European Institute of Oncology, Milan, Italy

Decoding leukemia stem cell RNA recoding
Catriona Jamieson, UCSD Moores Cancer Center, San Diego, Calif.

Competitive strategies of transformed HSCs: Lessons learned from CML biology
Emmanuelle Passegué

SRSF2 mutations impair hematopoietic differentiation by altering exonic splicing enhancer preference
Omar Abdel-Wahab, Memorial Sloan Kettering Cancer Center, New York, N.Y.

10:00 a.m.-10:15 a.m.

Concurrent Sessions 3-4
10:15 a.m.-12:15 p.m.
Concurrent Session 3: Lymphoma
Session Chairperson: Louis M. Staudt, National Cancer Institute, Bethesda, Md.
Therapies of lymphoma targeting oncogenic signaling pathways
Louis M. Staudt

Identification of targetable vulnerabilities in lymphoma
Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, Mass.

The genetic basis of diffuse large B-cell lymphoma
Laura Pasqualucci, Columbia University Irving Comprehensive Cancer Center, New York, N.Y.

Patient-derived tumorgrafts from primary peripheral T-Cell lymphoma represent innovative models to design patients’ tailored therapies
Giorgio Inghirami, Weill Cornell Medical College, New York, N.Y.

DLBCL tumors are sensitized to ferroptosis, a regulated form of nonapoptotic cell death
Wan Seok Yang, Columbia University, New York, N.Y.*

Concurrent Session 4: Myelodysplastic Syndrome and Myeloproliferative Neoplasms

Session Chairperson: Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, N.Y.
Role of JAK-STAT pathway activation in MPN pathogenesis and therapeutic response
Ross L. Levine

Interpreting the role of acquired gene mutations in defining clinical outcome and treatment response
Elli Papaemmanuil, Sanger Institute, Hinxton, U.K.

Molecular profiling of MDS for precision therapy
Seishi Ogawa, Kyoto University, Kyoto, Japan

Pathogenesis and clonal evolution of myeloproliferative neoplasms
Radek C. Skoda, University Hospital Basel, Basel, Switzerland

Mutant U2AF1 alters hematopoiesis and pre-mRNA splicing in transgenic mice
Cara Lunn Shirai, Washington University in St. Louis, St. Louis, Mo.*

12:15 p.m.-12:45 p.m.

Plenary Session 6: Epigenetics
Session Chairperson: Scott A. Armstrong, Memorial Sloan Kettering Cancer Center, New York, N.Y.
12:45 p.m.-3:00 p.m.

Targeting epigenetic mechanisms in leukemia
Scott A. Armstrong

DNA methylation, the cancer epigenome, and translational implications
Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, Md.

Epigenetic programming and therapy in germinal center derived B-cell lymphomas
Ari M. Melnick, Weill Cornell Medical College, New York, N.Y.

Chemical modulation of chromatin structure and function
James E. Bradner, Dana-Farber Cancer Institute, Boston, Mass.


3:00 p.m.

*Short talks from proffered abstracts